DK370486A - Hmg-coa-reduktaseinhibitor og fremgangsmaade til fremstilling deraf - Google Patents

Hmg-coa-reduktaseinhibitor og fremgangsmaade til fremstilling deraf Download PDF

Info

Publication number
DK370486A
DK370486A DK370486A DK370486A DK370486A DK 370486 A DK370486 A DK 370486A DK 370486 A DK370486 A DK 370486A DK 370486 A DK370486 A DK 370486A DK 370486 A DK370486 A DK 370486A
Authority
DK
Denmark
Prior art keywords
hmg
preparing
procedure
coa reductase
reductase inhibitor
Prior art date
Application number
DK370486A
Other languages
Danish (da)
English (en)
Other versions
DK370486D0 (da
Inventor
William F Hoffman
Edward Scolnick
Robert L Smith
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of DK370486D0 publication Critical patent/DK370486D0/da
Publication of DK370486A publication Critical patent/DK370486A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK370486A 1985-08-05 1986-08-04 Hmg-coa-reduktaseinhibitor og fremgangsmaade til fremstilling deraf DK370486A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/762,736 US4668699A (en) 1985-08-05 1985-08-05 Novel HMG-CoA reductase inhibitors

Publications (2)

Publication Number Publication Date
DK370486D0 DK370486D0 (da) 1986-08-04
DK370486A true DK370486A (da) 1987-02-06

Family

ID=25065902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK370486A DK370486A (da) 1985-08-05 1986-08-04 Hmg-coa-reduktaseinhibitor og fremgangsmaade til fremstilling deraf

Country Status (13)

Country Link
US (2) US4668699A (ko)
EP (1) EP0211416B1 (ko)
JP (1) JPS6233133A (ko)
KR (1) KR870002158A (ko)
AU (1) AU6084686A (ko)
CA (1) CA1291143C (ko)
DE (1) DE3681991D1 (ko)
DK (1) DK370486A (ko)
ES (1) ES2000842A6 (ko)
GR (1) GR862006B (ko)
IL (1) IL79530A0 (ko)
PT (1) PT83077B (ko)
ZA (1) ZA865779B (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4916162A (en) * 1986-05-05 1990-04-10 Merck & Co., Inc. Antihypercholesterolemic compounds
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4789682A (en) * 1987-03-17 1988-12-06 Merck & Co., Inc. Antihypercholesterolemic compounds
US4845237A (en) * 1987-04-15 1989-07-04 Merck & Co., Inc. Acylation process for the synthesis of HMG-CoA reductase inhibitors
PT88364A (pt) * 1987-09-02 1989-07-31 Merck & Co Inc Process for preparing novel hmg-coa reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4994494A (en) * 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4892884A (en) * 1987-12-21 1990-01-09 Rorer Pharmaceutical Corporation Novel hmg-coa reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4904692A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4866068A (en) * 1988-02-01 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5049696A (en) * 1988-04-11 1991-09-17 Merck & Co., Inc. Antihypercholesterolemic compounds
FI893004A (fi) * 1988-06-29 1989-12-30 Merck & Co Inc 5-oxygenerade hmg-coa-reduktas -inhibitorer.
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
US5073568A (en) * 1988-11-14 1991-12-17 Hoffmann-La Roche Inc. Antipsoriatic agents
US5200549A (en) * 1988-11-14 1993-04-06 Hoffman-La Roche Inc. Antipsoriatic agents
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5130306A (en) * 1989-03-13 1992-07-14 Merck & Co., Inc. 5-Oxygenated HMG-COA reductase inhibitors
US5132312A (en) * 1989-03-27 1992-07-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
IL90847A0 (en) * 1989-06-09 1990-02-09 Merck & Co Inc 3-keto hmg-coa reductase inhibitors and pharmaceutical compositions containing them
GB8915280D0 (en) * 1989-07-04 1989-08-23 British Bio Technology Compounds
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US4992429A (en) * 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
EP0415188B1 (en) * 1989-08-28 1996-03-20 F. Hoffmann-La Roche Ag Enzymatic method for determining analyte concentrations
US4946860A (en) * 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
US6630502B2 (en) 1990-05-15 2003-10-07 E.R. Squibb & Sons, Inc. Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
GB9100174D0 (en) * 1991-01-04 1991-02-20 British Bio Technology Compounds
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
JP2003012607A (ja) * 2001-06-26 2003-01-15 Mercian Corp 新規なメバスタチン誘導体
AU2002366444A1 (en) * 2001-11-08 2003-09-09 Merck & Co., Inc. Compounds useful in the treatment of anthrax
KR20060013632A (ko) 2002-05-17 2006-02-13 오쎄라 파마슈티걸즈, 인크. 백내장 및 다른 안질환 발병의 개선
US20040119052A1 (en) * 2002-12-20 2004-06-24 Beavers William Anthony Process for preparing alpha- and beta- methyl-gamma-butyrolactone and 3-methyltetrahydrofuran
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
CN104350036B (zh) * 2012-06-05 2017-05-17 帝斯曼知识产权资产管理有限公司 4‑烷酰氧基‑2‑甲基丁酸的生产方法
DK3638044T3 (da) * 2017-06-15 2024-06-10 Dsm Ip Assets Bv Frosne enzympellets
KR20200066690A (ko) 2017-10-16 2020-06-10 칭화대학교 메발로네이트 경로 억제제 및 이의 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4376863A (en) * 1981-08-21 1983-03-15 Merck & Co., Inc. Hypocholesterolemic fermentation products
JPS5835144A (ja) * 1981-08-27 1983-03-01 Sankyo Co Ltd Ｍｂ−５３０ｂ誘導体およびその製造法
EP0094443A1 (en) * 1982-05-17 1983-11-23 Merck & Co. Inc. 6(R)-(2-(8(S) (2,2-dimethylbutyryloxy)-2(S),6(S)-dimethyl-1,2,3,4,4a(S),5,6,7,8,8a(S)-decahydronaphthyl-1(S))ethyl)-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one, process for preparing and pharmaceutical composition containing the same
JPS59122483A (ja) * 1982-12-28 1984-07-14 Nippon Chemiphar Co Ltd 新規なモナコリン誘導体
EP0137445B1 (en) * 1983-10-11 1990-01-03 Merck & Co. Inc. Process for c-methylation of 2-methylbutyrates
JPH09122483A (ja) * 1995-10-31 1997-05-13 Matsushita Electric Ind Co Ltd 窒素酸化物・硫黄酸化物吸収剤

Also Published As

Publication number Publication date
KR870002158A (ko) 1987-03-30
IL79530A0 (en) 1986-11-30
EP0211416A2 (en) 1987-02-25
ZA865779B (en) 1987-03-25
JPS6233133A (ja) 1987-02-13
PT83077B (en) 1988-07-13
DK370486D0 (da) 1986-08-04
EP0211416A3 (en) 1987-09-23
DE3681991D1 (de) 1991-11-21
EP0211416B1 (en) 1991-10-16
US4851436A (en) 1989-07-25
AU6084686A (en) 1987-02-12
CA1291143C (en) 1991-10-22
ES2000842A6 (es) 1988-03-16
PT83077A (en) 1986-08-01
GR862006B (en) 1986-12-23
US4668699A (en) 1987-05-26

Similar Documents

Publication Publication Date Title
DK370486D0 (da) Hmg-coa-reduktaseinhibitor og fremgangsmaade til fremstilling deraf
DK317287D0 (da) Reduktase-inhibitorer
DK313086A (da) Phenoxyalkylisoxazol- eller -furanforbindelse og fremgangsmaade til fremstilling deraf
DK51286A (da) Desoxyadenosinphosphatforbindelser og fremgangsmaade til fremstilling afdisse
DK301886A (da) Furanon-derivater og fremgangsmaade til fremstilling heraf
DK335886D0 (da) Distamycinderivat og fremgangsmaade til fremstilling deraf
EP0403487A4 (en) Novel hmg-coa reductase inhibitors
DK277388A (da) Phosphorholdige hmg-coa-reduktase-inhibitorer, mellemprodukter og fremgangsmaade
DK485888D0 (da) Hmg-coa reduktaseinhibitor og fremgangsmaade til fremstilling deraf
DK335986A (da) Poly-4-aminopropyl-2-carboxamidoderivat og fremgangsmaade til fremstilling deraf
NO860092L (no) Korrosjons-inhibitor og fremgangsmaate til fremstilling derav.
DK251087D0 (da) Dopamin-beta-hydrolaseinhibitorer og fremgangsmaade til fremstilling deraf
NO850393L (no) Neglelakk og fremgangsmaate til fremstilling derav
DK486088D0 (da) Hmg-coa reduktaseinhibitor og fremgangsmaade til fremstilling deraf
DK422989A (da) Quinolin- og pyridinankre for hmg-coa-reductaseinhibitorer
DK515686A (da) Dopamin-beta-hydroxylase-inhibitorer og fremgangsmaade til fremstillingderaf
ZA874487B (en) Novel hmg-coa reductase inhibitors
DK50686D0 (da) Difficolforbindelse og fremgangsmaade til fremstilling deraf
IE851368L (en) Preparing hmg-coa reductase inhibitors
IE861739L (en) Hmg-coa reductase inhibitors
DK53887A (da) Emulgator og fremgangsmaade til fremstilling deraf
ZA894895B (en) 5-oxygenated hmg-coa reductase inhibitors
IE822652L (en) HMG-CoA REDUCTASE INHIBITORS
IE871654L (en) Novel hmg-coa reductase inhibitors
IE862071L (en) HMG CoA REDUCTASE INHIBITORS

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment